Incyte insider sales
WebFeb 8, 2024 · February 08, 2024 — 11:01 am EST. Incyte Corporation INCY missed on earnings in the fourth quarter of 2024. However, sales beat estimates driven by growth in patient demand for the lead drug ... WebWebsite: www.incyte.com Headquarters: Wilmington, DE Size: 501 to 1000 Employees Founded: 1991 Type: Company - Public (INCY) Industry: Biotech & Pharmaceuticals Revenue: $100 to $500 million (USD) Competitors: Genentech, Gilead Sciences, Vertex Pharmaceuticals Create Comparison
Incyte insider sales
Did you know?
WebApr 15, 2024 · In other Incyte news, EVP Maria E. Pasquale sold 60,024 shares of the stock in a transaction on Monday, January 30th. The shares were sold at an average price of $84.74, for a total value of $5,086,433.76. Following the completion of the sale, the executive vice president now directly owns 68,524 shares of the company's stock, valued at … WebApr 13, 2024 · Insider Buying and Selling. In related news, EVP Maria E. Pasquale sold 60,024 shares of Incyte stock in a transaction on Monday, January 30th. The stock was sold at an average price of $84.74 ...
WebApr 11, 2024 · Insider Trading Selling Shares $5.68 M Sold Last Quarter Proj. Earnings Growth 37.99% From $3.29 to $4.54 Per Share See Full Details Overall MarketRank ™ 2.80 … WebMay 3, 2024 · May 3, 2024 at 7:00 AM EDT. PDF Version. Total product and royalty revenues of $728 million in Q1’22 (+20% Y/Y) Jakafi® (ruxolitinib) net product revenues of $544 …
WebSep 10, 2024 · He also calls for Incyte's sales to grow at a 10% compounded annual rate. Incyte Pipeline 'Underappreciated' The pipeline also appears to be underappreciated. Incyte is testing Jakafi as a topical ... WebNov 2, 2024 · In Q3 2024 it had sales of $38 million, more than doubling its Q2 sales. Considerable time was devoted to discussing its sales ramp during the Q3 Incyte Analyst Conference. The number of potential ...
Web151 rows · Get the latest insider transactions for Incyte Corporation (INCY). Find out the total of insider shares held, purchased and sold. Get the detailed quarterly/annual income statement for Incyte Corporation (INCY). … Discover historical prices for INCY stock on Yahoo Finance. View daily, weekly or … Find out all the key statistics for Incyte Corporation (INCY), including valuation … Find the latest Incyte Corporation (INCY) stock discussion in Yahoo Finance's … View the basic INCY option chain and compare options of Incyte Corporation …
WebApr 15, 2024 · 3.00. Incyte presently has a consensus price target of $85.43, indicating a potential upside of 14.67%. MaxCyte has a consensus price target of $10.50, indicating a potential upside of 96.26% ... thermo scientific icap 6300WebMar 11, 2024 · Incyte's ruxolitinib, a type of non-steroidal anti-inflammatory medication called a JAK inhibitor, already makes up a major chunk of earnings, representing $2.22 billion of the company's $2.46 ... thermo scientific icapWebApr 15, 2024 · 3.00. Incyte currently has a consensus price target of $85.43, suggesting a potential upside of 14.67%. MaxCyte has a consensus price target of $10.50, suggesting a potential upside of 96.26% ... thermo scientific icap tq icp-msWebApr 15, 2024 · Insider Activity at Incyte In other Incyte news, EVP Maria E. Pasquale sold 60,024 shares of the firm’s stock in a transaction dated Monday, January 30th. The stock … tphelpbaseWebApr 12, 2024 · Ballentine Partners LLC acquired a new position in shares of Incyte Co. ( NASDAQ:INCY - Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,609 shares of the biopharmaceutical company's stock, valued at approximately $210,000. 3 S&P 500 … tph efcoreWebGet Incyte Corp (INCY:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. tphelps525 icloud.comWebNov 28, 2014 · We believe that the stock price of Incyte, a global biopharmaceutical company, is undervalued at current levels of $75. INCY stock is down 21% over the last … t pheasant\u0027s-eyes